TAD biopsy for HER2+ breast cancer with positive lymph nodes
Part of Cancer clinical trials.
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer that is HER2+ and has spread to at least one lymph node.
- You can walk and do normal daily activities (ECOG 0 or 1).
- You will receive standard chemo plus anti-HER2 therapy before surgery.
- The suspicious lymph node in your armpit was marked before treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a targeted surgical approach to remove only the suspicious lymph nodes under the arm for people with early-stage, hormone receptor positive, HER2 negative breast cancer. The goal is to see if this less extensive surgery is safe and effective when there is limited lymph node involvement.
This trial studies a treatment plan for early breast cancer that involves at least three suspicious lymph nodes on the ultrasound/imaging. It looks at whether a targeted technique—done before surgery with chemotherapy—can improve or guide care when surgery will remove the lymph nodes.
This trial studies an additional treatment given after chemotherapy for locally advanced breast cancer that has spread to specific underarm lymph nodes. It may help some people reduce cancer returning, especially when tumors match certain growth and spread features.
This trial is for women age 45 and older with early ER-positive breast cancer that has spread to the lymph nodes under the arm. It tests a surgery approach where the main tumor and only a few key lymph nodes (rather than many) are removed.
This study tests a more focused surgery approach to remove lymph nodes in the armpit for people with early breast cancer that has been found in 1–2 axillary lymph nodes. It may help guide more precise treatment while checking how well this approach works.
This Phase 3 trial compares two post-surgery drug plans for HER2-positive early breast cancer that has spread to nearby lymph nodes. It may help reduce cancer recurrence by testing which regimen works better after surgery.
Hear when a new HER2 Positive Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.